Oyster Point Pharma Inc Stock News

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -2.86% and 31.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET

Conference Call and Webcast Scheduled for March 7, 2022, 10:30 A.M. ET Conference Call and Webcast Scheduled for March 7, 2022, 10:30 A.M. ET

Conference Call and Webcast Scheduled for March 7, 2022, 10:30 A.M. ET Conference Call and Webcast Scheduled for March 7, 2022, 10:30 A.M. ET

Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2021 Results - Earnings Call Transcript

OYST earnings call for the period ending December 31, 2021.

OYST earnings call for the period ending December 31, 2021.

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -15.83% and 1,206.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Oyster Point Pharma press release (OYST): Q4 GAAP EPS of -$1.61 misses by $0.23.Revenue of $6.59M beats by $6.29M.As of December 31, 2021, cash, cash equivalents, and restricted…

PRINCETON, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused o

PRINCETON, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an overview of recent business highlights.

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -15.83% and 1,206.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

PRINCETON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced TYRVAYA TM Nasal Sprays placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively makes up an estimated 26 million lives, effective February 19, 2022. TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease.